Vir Biotech's hepatitis B therapy shows 4% cure rate with doublet (tobevibart/elebsiran) and 10% with triplet therapy, below ...

FDA clears Ensoma's trial of in vivo blood stem cell editing therapy for X-linked chronic granulomatous disease, following China's Yoltech earlier this year.

The White House outlined plans to force down prices of drugs sold in the US using the threat of tying costs to rates paid by ...

New data shows Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss, with 65% vs 40% of patients achieving ...

Wel­come back to End­points Week­ly — thanks for start­ing your Sat­ur­day with us. It was a busy week in the bio­phar­ma world. FDA Com­mis­sion­er Mar­ty Makary … ...

Iovance Therapeutics’ stock dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales ...

Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen's Lumakras & Bristol Myers' Krazati ...

Lonza said on Friday it does not expect any 'material financial impact' from current and potential pharma-specific tariffs.

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

Endpoints platform launches new profile system with improved account management features, including streamlined newsletter ...

Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price up by as much as 35% premarket Friday.

Insilico Medicine files third HKEX IPO attempt, as biotech develops rentosertib for IPF and other drugs with AI-driven ...